New Delhi, : In a timely intervention to ease pressure on critical healthcare supply chains, the Government of India has announced customs duty relief measures for the pharmaceutical and medical technology (MedTech) sectors, aiming to address ongoing supply constraints and rising input costs.

The move is designed to ensure the uninterrupted availability of essential raw materials, intermediates, and components required for the manufacturing of medicines and medical devices. By reducing customs duties on select imports, the government seeks to stabilize production cycles, improve supply continuity, and contain cost escalations impacting both manufacturers and end consumers.

Industry stakeholders have highlighted that global disruptions—driven by geopolitical tensions, logistics bottlenecks, and fluctuating commodity prices—have significantly strained supply chains for active pharmaceutical ingredients (APIs), medical device components, and specialty chemicals. The customs relief is expected to provide immediate cost support and enhance the sector’s resilience.

Officials indicated that the policy measure aligns with the government’s broader objective of strengthening healthcare manufacturing ecosystems, while also supporting India’s ambitions to become a global hub for pharmaceuticals and medical devices. The relief is likely to benefit both large manufacturers and MSMEs operating across the value chain.

Experts note that such targeted interventions are critical in maintaining affordability and accessibility of healthcare products, particularly during periods of global uncertainty. The move is also expected to complement ongoing initiatives focused on domestic manufacturing, supply chain diversification, and innovation-led growth in the healthcare sector.

The government is expected to monitor market conditions closely and may introduce additional measures, if required, to ensure stability in the pharma and MedTech industries.